Format

Send to

Choose Destination
Antiviral Res. 2015 Nov;123:70-7. doi: 10.1016/j.antiviral.2015.08.015. Epub 2015 Sep 2.

Ebola virus dynamics in mice treated with favipiravir.

Author information

1
INSERM, IAME, UMR 1137, F-75018 Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France.
2
Bernhard-Nocht-Institute for Tropical Medicine, 20359 Hamburg, Germany; German Centre for Infection Research (DZIF), Partner Site Hamburg, Germany.
3
Center for Modeling and Simulation in the Biosciences, BioQuant-Center, Heidelberg University, 69120 Heidelberg, Germany.
4
Aix Marseille Université, IRD French Institute of Research for Development, EHESP French School of Public Health, EPV UMR_D 190 "Emergence des Pathologies Virales", F-13385 Marseille, France; Institut Hospitalo-Universitaire Méditerranée Infection, F-13385 Marseille, France.
5
INSERM, IAME, UMR 1137, F-75018 Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France. Electronic address: jeremie.guedj@inserm.fr.

Abstract

The polymerase inhibitor favipiravir is a candidate for the treatment of Ebola virus disease. Here, we designed a mathematical model to characterize the viral dynamics in 20 mice experimentally infected with Ebola virus, which were either left untreated or treated with favipiravir at 6 or 8days post infection. This approach provided estimates of kinetic parameters of Ebola virus reproduction, such as the half-life of productively infected cells, of about 6h, and the basic reproductive number which indicates that virus produced by a single infected cell productively infects about 9 new cells. Furthermore, the model predicted that favipiravir efficiently blocks viral production, reaching an antiviral effectiveness of 95% and 99.6% at 2 and 6days after initiation of treatment, respectively. The model could be particularly helpful to guide future studies evaluating favipiravir in larger animals.

KEYWORDS:

Ebola; Favipiravir; Modeling; Viral kinetics

PMID:
26343011
DOI:
10.1016/j.antiviral.2015.08.015
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for HAL archives ouvertes
Loading ...
Support Center